Pharming Group (PHARM.AS) Stock Price
Pharming Group Price
Over the last 19 years Pharming Group grew revenue by 48.9% annually, reaching 326.12 M USD. Earnings per share have declined at 29.3% per year over the last 7 years. For Pharming Group, the net margin of 0.8% is down versus 8.4% a few years ago. The consensus 12-month price target for Pharming Group is 2.30 USD, about 141.4% above where the stock trades today. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus.
Pharming Group stock price
Pharming Group business model & stock analysis
Frequently asked questions about Pharming Group
Pharming Group NV operates under a unique business model. The company specializes in the development and commercialization of innovative biotherapeutics using its proprietary technology platform, known as the recombinant human C1 esterase inhibitor (rhC1INH). This technology allows Pharming Group to produce and deliver recombinant human proteins, addressing unmet medical needs in diseases such as hereditary angioedema (HAE) and lysosomal storage disorders. By leveraging their scientific expertise and strategic partnerships, Pharming Group NV aims to improve the quality of life for patients and create value for their stakeholders.
Pharming Group NV is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Pharming Group NV in the market include Biocryst Pharmaceuticals, CSL Behring, Grifols, and Takeda Pharmaceutical Company Limited.
Pharming Group NV is a biopharmaceutical company with a rich history and remarkable background. The company was established in 1988, headquartered in the Netherlands. Pharming focuses on the development and commercialization of innovative protein replacement therapies and precision medicines utilizing its proprietary technology platform. The company is renowned for its pioneering work in the field of recombinant human plasma proteins, particularly Recombinant Human C1 Inhibitor (rhC1INH). Pharming Group NV has successfully developed and marketed these life-saving treatments for hereditary angioedema (HAE) and acquired angioedema (AAE), significantly improving the lives of patients worldwide. With an impressive track record of scientific expertise and substantial market presence, Pharming Group NV continues to be a leading player in the biopharmaceutical industry.
Pharming Group NV has achieved several significant milestones. Notably, the company received approval for its lead product, Ruconest, by regulatory authorities in the United States and Europe. This approval allows Pharming Group NV to market Ruconest for the treatment of acute hereditary angioedema attacks, enhancing the company's market presence. Additionally, Pharming Group NV has successfully expanded Ruconest's sales and commercial footprint, securing distribution agreements in various countries. The company's consistent efforts in research and development have resulted in the exploration of new therapeutic areas, such as Pompe disease. Pharming Group NV's commitment to innovation and attaining regulatory approvals has paved the way for its growth and success in the biopharmaceutical industry.
Pharming Group NV is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates its North American headquarters. Additionally, Pharming Group NV has a significant presence in Europe, with offices and distribution networks in various countries such as the Netherlands, Germany, France, Italy, and the United Kingdom. Furthermore, the company has expanded its reach into Asia, particularly in important markets like Japan and South Korea. With its global presence, Pharming Group NV is able to effectively deliver its innovative biopharmaceutical products and therapies to patients across different continents.
Pharming Group NV represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Pharming is committed to developing innovative therapies for patients with unmet medical needs. They prioritize collaboration by partnering with research institutions, healthcare professionals, and patient organizations to advance scientific knowledge. Pharming's corporate philosophy revolves around improving the quality of life for patients through the development and commercialization of novel therapies. Their dedication to scientific excellence, integrity, and global outreach enables them to provide effective and life-changing therapies for patients around the world.
Analysts currently set an average price target of 2.47 USD for the Pharming Group stock (median: 2.30 USD), implying +159.5 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Pharming Group stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pharming Group to generate revenue of 381.11 M USD and earnings per share of 0.02 USD.
Converted at the current exchange rate, the Pharming Group share trades at 0.85 EUR (0.95 USD).
The Pharming Group share (PHARM.AS) is listed on 9 stock exchanges, including: London (0QCO.L), SIX (Zürich) (PHGN.SW), Frankfurt (PHGN.F), München (PHGN.MU), Düsseldorf (PHGN.DU), Amsterdam (PHARM.AS).
The Pharming Group NV is a biopharmaceutical company specialized in the development of innovative therapies for rare genetic diseases. The company is based in Leiden, Netherlands and is listed on the Euronext Amsterdam exchange. Pharming's business model is based on the research and development of biopharmaceuticals for the treatment of rare genetic diseases. The company focuses particularly on rare immune system disorders, including Hereditary Angioedema (HAE) and Lymphocytic Varicosis (LV). Pharming also conducts clinical trials for the treatment of other rare diseases. Pharming's products include Ruconest, a recombinant C1 esterase inhibitor (rhC1INH) used for the treatment of HAE. Ruconest is Pharming's flagship product and is marketed globally. The company has also developed a biosimilar version of Ruconest, which is produced under the brand name RucON. Pharming also has a pipeline of future products in development, including a recombinant factor VIII for the treatment of Hemophilia A and a recombinant factor IX for the treatment of Hemophilia B. The company is also working on the development of therapies for the treatment of rarer diseases such as Vascular Ehlers-Danlos Syndrome (EDS). Pharming pursues a diversified business model with a focus on research and development, production, and marketing of biopharmaceuticals. The company also operates its own manufacturing facility to ensure the production of biopharmaceuticals. Pharming also follows a strategic acquisition strategy to expand its product pipeline and increase market presence. Pharming's business model is based on a strong research and development pipeline, efficient production, a differentiated product range, and a strong marketing strategy to increase its presence in the markets. Pharming's focus on rare genetic diseases and continuous innovation in the treatment of these diseases make the company an important player in the biopharmaceutical market.
The expected revenue of Pharming Group is 381.11 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pharming Group is 15.83 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pharming Group is currently 45.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharming Group stock.
The price-to-sales ratio (P/S) of Pharming Group is currently 1.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharming Group stock.
The Eulerpool Quality Score for Pharming Group is 5/10.
The ISIN of Pharming Group is NL0010391025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pharming Group is A1H65A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pharming Group is PHARM.AS. The ticker symbol is used to trade Pharming Group shares on the stock exchange.
Pharming Group stock
Pharming Group Peer Group
Pharming Group Ticker
Pharming Group FIGI
All fundamentals and in-depth analysis of Pharming Group
Our stock analysis for Pharming Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.